A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma

British Journal of Cancer

Volumn 89, Issue 2, 2003, Pages 252-257

  Dalhoff, K ^a   Dancey, J ^b   Astrup, L ^c   Skovsgaard, T ^d   Hamberg, K J ^e   Lofts, F J ^f   Rosmorduc, O ^g   Erlinger, S ^h   Bach Hansen, J ⁱ   Steward, W P ^j   Skov, T ^e   Burcharth, F ^d   Evans, T R J ^k  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e LEO PHARMA A S   (Denmark)

^f ST GEORGE S HOSPITAL   (United Kingdom)

^g HÔPITAL SAINT ANTOINE   (France)

^h BEAUJON HOSPITAL   (France)

ⁱ AALBORG UNIVERSITY HOSPITAL   (Denmark)

^j LEICESTER ROYAL INFIRMARY   (United Kingdom)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; SEOCALCITOL; VITAMIN D DERIVATIVE;

ADVANCED CANCER; ARTICLE; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE CALCULATION; DRUG TOLERABILITY; EARLY CANCER; EVALUATION; FEMALE; HUMAN; HYPERCALCEMIA; LETHARGY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE FATIGUE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CALCITRIOL; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, CALCITRIOL; TREATMENT OUTCOME;

EID: 0041620332     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601104     Document Type: Article

References (37)

1. 3 analog, EB 1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in nude mouse model. Dis Colon Rectum 40: 317-321
2. 3 and its analogues, EB 1089 and CB 1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HEPG2. ANZ J Surg 71: 414-417
3. 3. Mol Endocrinol 7: 1307-1312
4. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC (1988) Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 67: 607-613
5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35: 421-430
6. Colston K, James SY, Ofori-Kuragu EA, Binderup L, Grant AG (1997a) Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 76: 1017-1020
7. Colston KW, James SY, Ofori-Kuragu EA, Binderup L, Grant AG (1997b) Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 76: 1017-1020
8. Colston KW, MacKay AG, James SY, Binderup L, Chandler S, Coombes RC (1992) EB 1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44: 2273-2280
9. Evans TRJ, Colston KW, Cunningham D, Anthoney DA, Gogas H, de Bono JS, Hamberg KJ, Skov T, Mansi JL (2002) A phase II study of the vitamin D analogue Seocalcitol (EB 1089) in patients with inoperable pancreatic cancer. Br J Cancer 86: 680-685
10. Evans TRJ, Kaye SB (1999) Retinoids: present role and future potential. Br J Cancer 80: 1-8
11. Falkson G, MacIntyre J, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer. Cancer 54: 970-977
12. Gallo C, Daniele B, Gaeta GB, Pignata S (1998) Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trail. Lancet 352: 17-20
13. Gehan E (1961) The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13: 346-353
14. Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239-253
15. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok L, Cirera A (1998) Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trail. J Clin Oncol 16: 411-417
16. Gulliford T, English J, Colston KW, Menday P, Moeller S, Coombes RC (1998) A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 78: 6-13
17. 3 and some selected analogues on the invasiveness of human mammary carcinoma cells in vitro. In Vitamin D: A Pluripotent Steroid Hormone. Norman A, Bouillon R, Thomasset M (eds) pp. 508-509. de Gruyter: Berlin
18. Hansen CM, Hamberg KJ, Binderup E, Binderup L (2000) Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 6: 803-828
19. Hansen CM, Mäenpää PH (1997) EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem Pharmacol 54: 1173-1179
20. Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris A, Todo S, Tzakis A, van Thiel D, Carr B, Selby R, Madariaga J (1991) Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214: 221-229
21. Jääskeläinen T, Ryhänen S, Mahonen A, DeLuca HF, Mäenpää P (2000) Mechanism of action of superactive vitamin D analogs through regulated receptor degradation. J Cell Biochem 76: 548-558
22. James SY, Mercer E, Brady M, Binderup L, Colston KW (1998) EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 125: 953-962
23. Lokeshwar BL, Schwartz GG, Seizer MG, Burnstein KL, Zhuang S-H, Block NL, Binderup L (1999) Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB 1089. Cancer Epidemiol Biomarkers Prev 8: 241-248
24. Mahonen A, Pirskanen A, Mäenpää P (1991) Homologous and heterologous regulation of 1,25-dihydroxyvitamin D-3 receptor mRNA levels in human osteosarcoma cells. Biochem Biophys Acta 1088: 111-118
25. 3 and their combination. Cancer Lett 75: 35-39
26. 3: in vitro translation to characterize size and hormone-dependent regulation. Proc Natl Acad Sci USA 84: 354-358
27. Mathiasen IS, Colston KW, Binderup L (1993) EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Mol Biol 46: 365-371
28. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. N Engl J Med 341: 1165-1173
29. McDonell DP, Mangelsdorf DJ, Pike JW, Haussler MR, O'Malley BW (1987) Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science 235: 1214-1217
30. 3 receptor mRNA in the proliferation of hepatocellular carcinoma. Hepatogastroenterology 47: 468-472
31. Nagasue N, Yukaya H, Chang Y, Yamanoi A, Kohno H, Hayashi T, Nakamura T (1990) Assessment of pattern and treatment of intrahepatic recurrence after resection of hepatocellular carcinoma. Surg Gynecol Obstet 171: 217-222
32. Parkin D, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594-606
33. 3 (VD) receptor in human liver cancer cell lines and effect of VD on their proliferation. Acta Hepatol Japan 30: 338-344
34. 3 receptor in human liver cancer tissue. Acta Hepatol Japan 29: 1612-1618
35. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-1028
36. Yamada R, Kishi K, Sonomura T, Tsuda M, Nomura S, Satoh M (1990) Trancatheter arterial embolization in unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 13: 135-139
37. Zaman SN, Johnson RD, Johnson PJ, Melia WM, Portmann BC, Williams R (1985) Risk factors in development of hepatocellular carcinoma in cirrhosis: Prospective study of 613 patients. Lancet 1: 1357-1360